SELLAS Life Sciences Group, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Cost of revenue | $0 | $0 | $0 | $100,000 | $200,000 |
| Cash from operations | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
Shares outstanding 186.0M · Free float 98.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.